Beryl Drugs Q2 Results
- BSE: 524606
- NSE: -
- ISIN: INE415H01017
- Sector: Biotechnology & Drugs
BSE
19.95
-0.04 (-0.20%)
-0.04 (-0.20%)Volume102.00
Updated: Thu 22 May, 2025 | 11:22:16
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Beryl Drugs Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 24 | Jun 24 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 5.61 | 6.25 | -10.16% | 5.61 | N/A |
| Selling/ General/ Admin Expenses Total | 0.50 | 0.50 | 0.99% | 0.50 | N/A |
| Depreciation/ Amortization | 0.33 | 0.28 | 18.85% | 0.33 | N/A |
| Other Operating Expenses Total | 1.90 | 1.35 | 40.23% | 1.90 | N/A |
| Total Operating Expense | 5.41 | 5.58 | -3.03% | 5.41 | N/A |
| Operating Income | 0.20 | 0.67 | -70.04% | 0.20 | N/A |
| Net Income Before Taxes | 0.11 | 0.50 | -78.27% | 0.11 | N/A |
| Net Income | 0.01 | 0.37 | -98.12% | 0.01 | N/A |
| Diluted Normalized EPS | 0.01 | 0.73 | -98.14% | 0.01 | N/A |